The earnings call highlighted significant revenue growth driven by the successful launch of CGuard Prime in the U.S. and strong international performance. Financially, the company showed improved gross margins and a strengthened cash position due to successful financing. However, increased operating expenses and a higher net loss were noted as challenges. Overall, the positive achievements and growth prospects outweighed the financial challenges.

Company Guidance

During the InspireMD Third Quarter 2025 Earnings Conference Call, the company reported a total revenue of $2.5 million, marking a 39% year-over-year increase and over 40% sequential growth from the previous quarter. This growth was driven by the strong initial U.S. launch of the CGuard Prime carotid stent, following FDA approval in late June, and steady international demand. U.S. revenue for the quarter reached $497,000, while international revenue was $2.0 million, an increase of 12% from the previous year. Gross profit more than doubled to $864,000, with a gross margin of 34.2%, up from 22.9% the previous year. The company reported a net loss of $12.7 million or $0.17 per share. As of September 30, 2025, cash and cash equivalents stood at $63.4 million, bolstered by recent financing events. Looking ahead, InspireMD anticipates fourth-quarter revenue between $2.5 million and $3.0 million, with continuous growth expected from U.S. sales and consistent international demand.

Significant Revenue Growth

InspireMD's total revenue for the third quarter of 2025 reached $2.5 million, representing a year-over-year growth of 39% and sequential growth of over 40% since the last quarter.

Successful Launch of CGuard Prime in the U.S.

The U.S. revenue for the third quarter was $497,000, marking the first quarter of U.S. commercial revenue following the FDA approval in June 2025.

Strong International Performance

International revenue for the third quarter was $2.0 million, an increase of 12% compared to the third quarter of 2024, driven by increased usage in over 30 markets and favorable foreign exchange impacts.

Gross Margin Improvement

Gross profit increased by over 100% to $864,000 with a gross margin increase to 34.2% from 22.9% in the previous year.

Strong Financial Position

Cash and cash equivalents and marketable securities were $63.4 million as of September 30, 2025, due to successful financing events raising a total of $58 million.

Expansion of Clinical Trials

Progress in clinical trials such as C-GUARDIANS II and III, with expected FDA clearance and launches in mid-2026 and mid-2027 respectively, showcasing the versatility and clinical value of the platform.

Appointment of New Chief Medical Officer

Dr. Peter Soukas was appointed as the new Chief Medical Officer to oversee clinical and medical topics, enhancing the company's clinical excellence and market awareness.

InspireMD (NSPR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NSPR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 10, 2026	2025 (Q4)	-0.20 / -	-0.19	―	―	―
Nov 04, 2025	2025 (Q3)	-0.20 / -0.17	-0.16	-6.25% (-0.01)	―
Aug 05, 2025	2025 (Q2)	-0.26 / -0.26	-0.22	-18.18% (-0.04)	―
May 09, 2025	2025 (Q1)	-0.20 / -0.22	-0.21	-4.76% (-0.01)	―
Mar 12, 2025	2024 (Q4)	-0.20 / -0.19	-0.16	-18.75% (-0.03)	―
Nov 12, 2024	2024 (Q3)	-0.20 / -0.16	-0.15	-6.67% (-0.01)	―
Aug 06, 2024	2024 (Q2)	-0.19 / -0.22	-0.24	8.33% (+0.02)	―
May 14, 2024	2024 (Q1)	-0.18 / -0.21	-0.53	60.38% (+0.32)	―
Mar 06, 2024	2023 (Q4)	-0.19 / -0.16	-0.6	73.33% (+0.44)	―
Nov 06, 2023	2023 (Q3)	-0.14 / -0.15	-0.58	74.14% (+0.43)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NSPR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 04, 2025	$2.29	$2.12	-7.42%
Aug 05, 2025	$2.67	$2.45	-8.24%
May 09, 2025	$2.60	$2.60	0.00%
Mar 12, 2025	$2.79	$2.81	+0.72%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does InspireMD (NSPR) report earnings?

InspireMD (NSPR) is schdueled to report earning on Mar 10, 2026, TBA (Confirmed).

What is InspireMD (NSPR) earnings time?

InspireMD (NSPR) earnings time is at Mar 10, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is NSPR EPS forecast?

NSPR EPS forecast for the fiscal quarter 2025 (Q4) is -0.2.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing